The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease

Igor A Sobenin, Valentin V Pryanishnikov, Lyudmila M Kunnova, Yevgeny A Rabinovich, Danik M Martirosyan, Alexander N Orekhov, Igor A Sobenin, Valentin V Pryanishnikov, Lyudmila M Kunnova, Yevgeny A Rabinovich, Danik M Martirosyan, Alexander N Orekhov

Abstract

The double-blinded placebo-controlled randomized study has been performed in 51 coronary heart disease (CHD) patients to estimate the effects of time-released garlic powder tablets Allicor on the values of 10-year prognostic risk of acute myocardial infarction (fatal and non-fatal) and sudden death, with the respect of secondary CHD prevention. It has been demonstrated that 12-month treatment with Allicor results in the significant decrease of cardiovascular risk by 1.5-fold in men (p < 0.05), and by 1.3-fold in women. The above results were equitable also in terms of relative risks. The main effect that played a role in cardiovascular risk reduction was the decrease in LDL cholesterol by 32.9 mg/dl in men (p < 0.05), and by 27.3 mg/dl in women. Thus, the most significant effects were observed in men, while in women the decrease of cardiovascular risk appeared as a trend that might be due presumably to the insufficient sample size. Since Allicor is the remedy of natural origin, it is safe with the respect to adverse effects and allows even perpetual administration that may be crucial for the secondary prevention of atherosclerotic diseases in CHD patients.

References

    1. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation. 2002;105(3):310–315. doi: 10.1161/hc0302.102575.
    1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) JAMA. 2002;288:2981–2997. doi: 10.1001/jama.288.23.2981.
    1. Yoshiya Hata. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. American Journal of Clinical Nutrition. 1996;64:767–71.
    1. Aviello G, Abenavoli L, Borrelli F, Capasso R, Izzo AA, Lembo F, Romano B, Capasso F. Garlic: empiricism or science? Nat Prod Commun. 2009;4(12):1785–96.
    1. Yeh YY, Yeh SM. Garlic reduces plasma lipids by inhibiting hepatic cholesterol and triacylglycerol synthesis. Lipids. 1994;29:189–93. doi: 10.1007/BF02536728.
    1. Liu L, Yeh YY. Water-soluble organosulfur compounds of garlic inhibit fatty acid and triglyceride synthesis in cultured rat hepatocytes. Lipids. 2001;36:395–400. doi: 10.1007/s11745-001-0734-4.
    1. Gebhardt R. Multiple inhibitory effects of garlic extracts on cholesterol biosynthesis in hepatocytes. Lipids. 1993;28:613–9. doi: 10.1007/BF02536055.
    1. Yeh YY, Liu L. Cholesterol-lowering effects of garlic extracts and organosulfur compounds: human and animal studies. J Nutr. 2001;131:989S–93S.
    1. Ackermann RT, Mulrow CD, Ramirez G, Gardner CD, Morbidoni L, Lawrence VA. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med. 2001;161(6):813–24. doi: 10.1001/archinte.161.6.813.
    1. Agarwal KC. Therapeutic actions of garlic constituents. Med Res Rev. 2003;16:111–24. doi: 10.1002/(SICI)1098-1128(199601)16:1<111::AID-MED4>;2-5.
    1. Gupta N, Porter TD. Garlic and garlic derived compounds inhibit human squalene monooxygenase. J Nutr. 2001;131:1662–7.
    1. Ackermann RT. et al.Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med. 2001;161:813–24. doi: 10.1001/archinte.161.6.813.
    1. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Muenster (PROCAM) study. Circulation. 2002;105:310–5. doi: 10.1161/hc0302.102575.
    1. International Task Force for Prevention of Coronary Heart Disease. Pocket guide to prevention of coronary heart disease. Grunwald, Germany: Borm Bruckmeier Verlag GmBH; 2003.
    1. Tunstall-Pedoe H. et al.Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet. 1999;353:1547–57. doi: 10.1016/S0140-6736(99)04021-0.
    1. Bordia A, Verma SK, Srivastava KC. Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids. 1998;58:257–63. doi: 10.1016/S0952-3278(98)90034-5.
    1. Voss R. et al.Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Muenster Study (PROCAM) using neural networks. Int J Epidemiol. 2002;31:1253–62. doi: 10.1093/ije/31.6.1253.
    1. Gotto AM, Jr, Blood lipids and coronary heart disease. New York: International Lipid Information Bureau; 2000. The ILIB lipid handbook for clinical practice.
    1. Silagy C, Neil A. Garlic as a lipid lowering agent - a meta-analysis. J R Coll Physicians Lond. 1994;28:39–45.
    1. Berthold HK, Sudhop T. Garlic preparations for prevention of atherosclerosis. Curr Opin Lipidol. 1998;9:565–9. doi: 10.1097/00041433-199812000-00008.
    1. Bordia A, Verma SK, Srivastava KC. Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids. 1996;55:201–5. doi: 10.1016/S0952-3278(96)90099-X.
    1. Andrianova IV, Fomchenkov IV, Orekhov AN. Hypotensive effect of long-acting garlic tablets allicor (a double-blind placebo-controlled trial) Ter Arkh. 2002;74:76–8.
    1. Auer W. et al.Hypertension and hyperlipidaemia: garlic helps in mild cases. Br J Clin Pract Suppl. 1990;69:3–6.
    1. Bordia A. Effect of garlic on blood lipids in patients with coronary heart disease. Am J Clin Nutr. 1981;34:2100–3.
    1. Ernst E. Cardiovascular effects of garlic (Allium sativum): a review. Pharmatherapeutica. 1987;5:83–9.
    1. Silagy CA, Neil HA. A meta-analysis of the effect of garlic on blood pressure. J Hypertens. 1994;12:463–8. doi: 10.1097/00004872-199404000-00017.
    1. Andrianova IV. et al.Effect of the garlic tablets allicor on thrombocyte aggregation in vitro and ex vivo. Biull Eksp Biol Med. 1997;124:97–100. doi: 10.1007/BF02445068.
    1. Andrianova IV. et al.Use of allikor for the normalization of fibrinolysis and hemostasis in patients with chronic cerebrovascular diseases. Klin Med (Mosk) 2001;79:55–8.
    1. Block E. The chemistry of garlic and onions. Sci Am. 1985;252:114–9. doi: 10.1038/scientificamerican0385-114.
    1. Yeh YY, Liu L. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. J Nutr. 2001;131:989S–93S.
    1. Kannel WB. et al.Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. Am Heart J. 1986;112:825–36. doi: 10.1016/0002-8703(86)90481-3.
    1. Iberl B. et al.Quantitative determination of allicin and alliin from garlic by HPLC. Planta Med. 1990;56:320–6. doi: 10.1055/s-2006-960969.
    1. Stamler J. et al.Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts. Cardiology. 1993;82:191–222. doi: 10.1159/000175868.
    1. Orekhov AN. et al.Direct anti-atherosclerosis-related effects of garlic. Ann Med. 1995;27:63–5. doi: 10.3109/07853899509031938.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren